US market focus Allergy Therapeutics has a core European commercial presence and a stated focus on expanding into the US market, presenting a key expansion opportunity for sales teams to introduce existing vaccine platforms and pipeline candidates to US distributors, healthcare providers, and payers.

R&D pipeline A diversified pipeline includes vaccines for grass, tree, and house dust mite, plus a peanut allergy vaccine in pre-clinical development, enabling cross-sell and partnership discussions around adjunctive adjuvant systems and collaborative clinical programs.

Financial capacity Recent financing of approximately £55 million and a loan facility strengthen balance sheet, supporting initiatives such as market expansion, manufacturing scale-up, and accelerated clinical development conversations with potential strategic investors or co-development partners.

Executive growth Recent appointments at executive and board levels, including chief strategy officer and independent directors, offer opportunities to leverage strategic introductions, governance signals, and advisory collaborations to accelerate commercial partnerships and market access strategies.

Industry engagement Active participation in AAAAI/WAO congresses and other industry events signals ongoing thought leadership and opportunities to schedule physician-facing dialogs, payer discussions, and collaboration talks with researchers and biotech partners.